Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine and Mindfulness for Opioid Use Disorder
NCT06642181Phase 1Recruiting
- Sponsor
- Rutgers University
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of guanfacine in opioid use disorder (OUD) (4 arms), sponsored by Rutgers University. Primary endpoints: Opioid Craving at 6 weeks, Anxiety at 6 weeks and 6 more. Started Jul 2025; status: recruiting.
02
Drugs
guanfacine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06642181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642181.